Methenamine Hippurate Compared to Typical Antibiotic Prophylaxis in the Prevention of Urinary Tract Infection Following Intradetrusor OnabotulinumtoxinA Injection for Treatment of Overactive Bladder: a Randomized Controlled Non-Inferiority Trial

The goal of this clinical trial is to compare methenamine hippurate prophylaxis to routine antibiotic prophylaxis following onabotulinumtoxinA (BOTOX-A) injections in women with overactive bladder (OAB). Participants will be randomly selected to receive one of the two post-procedural prophylaxis medications. The primary outcome measure will be urinary tract infection (UTI) rates within 30 days from the BOTOX-A procedure. Secondary outcomes will assess patient satisfaction with the two post-procedural prophylaxis medications.

开始日期2025-05-15

申办/合作机构

Women & Infants Hospital of Rhode Island

NCT06710899

/ Not yet recruiting早期临床1期

Does Vitamin C Improve the Efficacy of Methenamine Hippurate (Hiprex®) in Prophylaxis of Recurrent Urinary Tract Infections? A Proof of Concept Study

A single centre proof of concept study to assess whether Vitamin C improves the efficacy of Methenamine Hippurate (Hiprex®) in the prophylaxis of recurrent urinary tract infections (rUTIs) in women

开始日期2025-03-01

申办/合作机构

University Hospitals of North Midlands NHS Trust

NCT06810687

/ RecruitingN/A

Is Methenamine Prophylaxis for Urinary Tract Infection After Midurethral Sling as Effective as Antibiotic Prophylaxis? A Randomized Controlled Trial

Stress urinary incontinence (SUI) affects at least 40% of women in the United States. Synthetic polypropylene mid-urethral slings (MUS) are the gold standard treatment for SUI. Post-operative urinary tract infections (UTI) are one of the most common complications after MUS placement. Some studies have demonstrated that MUS placement can increase the risk of UTI up to 21-34%.
Post-operative UTI can lead to significant healthcare and patient burden. This additional burden further contributes to an estimated annual cost of $1.6 billion for UTI management in the United States. With increased antibiotic usage, there is simultaneous increase in bacterial resistance leading to treatment refractory UTI.
The investigators prescribe post-operative antibiotics prophylactically for 3 days after MUS placement with or without concurrent pelvic reconstructive surgery based on prior literature recommending post-operative prophylaxis. There is a greater emphasis on limiting antibiotic use given the trend of development of bacterial resistance. There are studies supporting alternatives such as methenamine for recurrent UTI prophylaxis treatment, but there are limited studies evaluating methenamine for UTI prophylaxis after MUS.

开始日期2025-01-30

申办/合作机构

Atlantic Health System - Atlantic Rehabilitation Institute

100 项与马尿酸乌洛托品相关的临床结果

登录后查看更多信息

100 项与马尿酸乌洛托品相关的转化医学

登录后查看更多信息

100 项与马尿酸乌洛托品相关的专利（医药）

登录后查看更多信息

523

项与马尿酸乌洛托品相关的文献（医药）

2025-09-01·JOURNAL OF MOLECULAR BIOLOGY

A key region of Tau that is able to drive assembly and modulate inhibition by Hydromethylthionine

Article

作者: Rickard, Janet E ; Serpell, Louise C ; Simpson, Michael ; Al-Hilaly, Youssra K ; Harrington, Charles R ; Storey, John M D ; Wischik, Claude M

Tau_297-391 (dGAE) forms paired helical filaments in vitro that resemble those deposited in Alzheimer's disease brain tissue. We have previously shown that hydromethylthionine (HMT) has the ability to inhibit dGAE self-assembly at sub-stoichiometric ratios. Here, we examined two regions of tau within the core filament-forming region that possess high self-assembly propensity sequences and have explored their ability to form filaments and whether their self-assembly can be inhibited by HMT. We confirm that tau_306-323 self-assembles to form filaments but that fibrillogenesis is not inhibited by HMT. Previous work by others has shown that tau_350-362 (PAM4) forms assemblies that recapitulate the C-shaped structure of paired helical filaments. Here, a chiral spectral circular dichroism fingerprint shows that HMT binds to tau350-362 and we reveal that HMT inhibits assembly. We conclude that the region important for assembly and inhibition is formed by the inner C-shaped region of tau and suggest that the central region involved in filament assembly may associate with HMT to prevent self-assembly.

2025-06-09·ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH

Stepwise leaching rare earth from weathered crust elution-deposited rare earth ores by the inhibition leaching of aluminum with HMTA.

Article

作者: Tang, Yuchen ; Chi, Ruan ; Wu, Ming ; Cui, Wenqian ; Xu, Zhigao ; He, Zhengyan ; Zuo, Qin ; Qu, Jun

In the leaching process of rare earth (RE) from weathered crust elution-deposited rare earth ores (WCE-DREO), the exchangeable impurity ions will also be exchanged and enter the RE leachate. Impurity removal must be treated before precipitating RE, which often causes the serious loss of RE and environmental pollution. Therefore, anti-impurity leaching of RE from WCE-DREO was investigated with hexamethylenetetramine (HMTA) as an impurity inhibitor and ammonium sulfate (AS) as a leaching agent. HMTA was first injected into the RE ores at a concentration of 0.8 wt%, liquid/solid of 0.5:1, and natural pH. Then, the injection solution was replaced with 2 wt% AS at liquid/solid of 0.5:1 and natural pH. The leaching efficiency of impurity Al could decrease to 5.99%. Without impurity removal, the RE leachate can be directly precipitated to obtain RE products with high quality. The leaching efficiency of RE was 92.95%, which was slightly higher than the traditional leaching technology with a single AS. The stepwise anti-impurity leaching technology simplifies the recovery process of RE, which benefits the green and high-efficiency exploitation of WCE-DREO. The physicochemical properties of RE ores and tailings were analyzed by modern analytical techniques to reveal the anti-impurity leaching mechanism. In the HMTA anti-impurity stage, HMTA can promote the conversion of exchangeable Al to adsorbed hydroxyl Al in RE ores. The adsorbed hydroxyl Al thinly attached to the surface of mineral particles is hard to be leached by leaching agent and retained in the RE ore in the AS leaching stage.

2025-06-01·PHYTOCHEMICAL ANALYSIS

HPLC Fingerprint Combined With Chemometrics and Multicomponent Content Determination for Quality Evaluation and Control of Huangma Tincture

Article

作者: Shang, Si‐yang ; Qiu, Jing ; Leng, Jing ; Zhou, Peng ; Li, Jie

ABSTRACT:

Introduction:

Huangma Tincture (HMT) is a Chinese patent medicine with a history of clinical use for more than 60 years, widely used for treating dermal chronic ulcer such as diabetic foot ulcer. However, the overall quality evaluation and control method of HMT has not yet been researched.

Objective:

The aim of this study is to establish a comprehensive quality evaluation and control method for HMT based on high‐performance liquid chromatography (HPLC) fingerprint, chemometrics, and multicomponent content determination.

Methods:

Establishing chemical fingerprint of HMT and carrying out similarity analysis comprehensively reflect the consistency of the formulation in terms of chemical composition. Chemometrics analyses, including hierarchical cluster analysis (HCA), principal component analysis (PCA), and orthogonal partial least squares‐discriminant analysis (OPLS‐DA), were performed to identify components crucial to quality differences. The content of five potential bioactive ingredients (brucine, strychnine, jatrorrhizine, coptisine, and berberine hydrochloride) was determined as a supplementary quality control measure.

Results:

HPLC fingerprint of HMT with similarity index > 0.990 was established, in which five common compounds (brucine, strychnine, jatrorrhizine, coptisine, and berberine hydrochloride) were identified. HCA, PCA, and OPLS‐DA results, validated through 200 permutation tests, were basically consistent. The contents of brucine, strychnine, jatrorrhizine, coptisine, and berberine hydrochloride in 20 batches of HMT samples were 0.2088–0.5556, 0.2599–0.9868, 0.1358–0.2092, 0.2634–0.6843, and 1.8301–2.7826 mg/mL, respectively.

Conclusion:

HPLC fingerprint combined with chemometrics and multicomponent content determination considering both effect and toxicity provides a robust method for the comprehensive quality evaluation and control of HMT.

项与马尿酸乌洛托品相关的新闻（医药）

2025-03-12

·ETPharma

Zydus Methenamine Hippurate tablet gets FDA final nod

New Delhi: Zydus Lifesciences announced its final approval from the US Food and Drug Administration to manufacture and market Methenamine Hippurate tablet in the country’s drug market. The drug is indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. Methenamine Hippurate tablets is a generic drug and the company will manufacture the drugs at its Ahmedabad facility . As per IQVIA analysis in the last twelve month period ending January 2025, Methenamine Hippurate tablets had reported net sales of $32.6 million in the United States. Post this approval, the Indian drug maker now has 419 approvals and has filed 483 ANDAs since the commencement of the filing process in FY 2003-04. By Online Bureau ,

上市批准

2024-08-23

·ETPharma

Govt bans 156 medicines including antibiotics, painkillers, multivitamins: Here is the full list

New Delhi: In a significant move aimed at safeguarding public health, the Indian government has banned 156 fixed-dose combination (FDC) drugs, including a variety of antibiotics, painkillers, multivitamins, and medications for treating fever and hypertension. This decision marks the largest crackdown on FDCs since 2016, when 344 such drugs were prohibited. The Union Ministry of Health and Family Welfare issued a gazette notification on Thursday, officially prohibiting the manufacture, sale, and distribution of the banned FDCs. The ban was based on the recommendations of an expert panel that reviewed a total of 324 FDCs. Impact on Pharmaceutical Industry The banned FDCs include popular combinations such as mefenamic acid and paracetamol injections, commonly used for pain relief and fever, and omeprazole magnesium with dicyclomine HCl, used to treat abdominal pain. The ban is expected to impact major pharmaceutical companies, including Sun Pharmaceuticals, Cipla, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, and Alkem Laboratories. Fixed Dose Combinations Drug Banned List Here is a table listing all 156 banned Fixed Dose Combinations (FDCs) SN Fixed Dose Combination (FDC) 1 Amylase + Protease + Glucoamylase + Pectinase + Alpha Galactosidase + Lactase + Beta-Gluconase + Cellulase + Lipase + Bromelain + Xylanase + Hemicellulase + Malt diastase + Invertase + Papain 2 Antimony Potassium Tartrate + Dried Ferrous Sulphate 3 Benfotiamine + Silymarin + L-Ornithine L-aspartate + Sodium Selenite + Folic acid + Pyridoxine hydrochloride 4 Bismuth Ammonium Citrate + Papain 5 Cyproheptadine HCl + Thiamine HCl + Riboflavine + Pyridoxine HCl + Niacinamide 6 Cyproheptadine Hydrochloride + Tricholine Citrate + Thiamine Hydrochloride + Riboflavine + Pyridoxine Hydrochloride 7 Rabeprazole Sodium (As enteric coated tablet) + Clidinium Bromide + Dicyclomine HCl + Chlordiazepoxide 8 Fungal Diastase + Papain + Nux vomica Tincture + Cardamom Tincture + Casein Hydrolysed + Alcohol 9 Mefenamic Acid + Paracetamol Injection 10 Omeprazole Magnesium + Dicyclomine HCl 11 S-adenosyl methionine + Metadoxine + Ursodeoxycholicacid BP + L-Methylfolate Calcium eq. to L- Methylfolate + Choline bitartratee + Silymarin + L-ornithine Laspartate + Inositol + Taurine 12 Silymarin + Thiamine Mononitrate + Riboflavin + Pyridoxine HCl + Niacinamide + Calcium pantothenate + Vitamin B12 13 Silymarin + Pyridoxine HCl + Cyanocobalamin + Niacinamide + Folic Acid 14 Silymarin + Vitamin B6 + Vitamin B12 + Niacinamide + Folic acid + Tricholine Citrate 15 Sodium Citrate + Citric Acid Monohydrate Flavored with Cardamom Oil, Caraway Oil, Cinnamon Oil, Clove Oil, Ginger Oil + Alcohol 16 Sucralfate + Acelofenac 17 Sucralfate + Domperidone + Dimethicone 18 Sucralfate + Domperidone 19 Tincture Ipecacuanha + Tincture Urgenia + Camphorated Opium Tincture + Aromatic Spirit of Ammonia + Chloroform + Alcohol 20 Ursodeoxycholic Acid + Metformin HCl 21 Weak Ginger tincture + Aromatic Spirit of Ammonia + Peppermint Spirit + Chloroform + Sodium Bicarbonate + Compound Cardamom + Alcohol 22 Sucralfate + Pantoprazole Sodium + Zinc Gluconate + Light Magnesium Carbonate 23 Aloe + Vitamin E Soap 24 Povidone Iodine+ Metronidazole + Aloe 25 Azelaic acid + Tea Tree Oil + Salicylic acid + Allantoin + Zinc oxide + Aloe vera + Jojoba oil + Vitamin E + Soap noodles 26 Azithromycin + Adapalene 27 Calamine + Aloes + Allantoin 28 Calamine + Diphenhydramine Hydrochloride + Aloe + Glycerine + Camphor 29 Chlorphenesin + Zinc oxide + Starch 30 Clindamycin Phosphate + Zinc acetate 31 Gamma Benzene Hexachloride + Benzocaine 32 Glucosamine hydrochloride + Diacerein + Menthol + Camphor + Capsaicin 33 Hydroxyquinone 2.0%w/w + Octyl Methoxycinnamate 5.0% w/w + Oxybenzone 30 % w/w 34 Ketoconazole +Zinc Pyrithione +D-Panthenol +Tea Tree Oil +Aloes 35 Ketoconazole +Aloe vera+ Vitamin A Acetate 36 Ketoconazole +Aloes + ZPTO 37 Kojic Acid +Arbutin +Octinoxate +Vitamin E + Mulberry 38 Lornoxicam +capsaicin +menthol+ camphor 39 Lornoxicam + Thiocolchicoside +Oleum Lini +Menthol + Methyl salicylate 40 Menthol + Aloe vera Topical Spray 41 Menthol +Lignocaine HCl +Aloe vera gel +Clotrimazole +Diphenhydramine 42 Miconazole nitrate + Gentamicin + Fluocinolone Acetonide +Zinc Sulphate 43 Miconazole +Tinidazole 44 Minoxidil +Aminexil+ Alcohol 45 Minoxidil +Azelaic acid + saw palmetto 46 Minoxidil +Aminexil 47 Pine Bark extract+ Kojic acid +Sodium Ascorbyl Phosphate 48 Povidone Iodine +Tinidazole +Zinc sulphate 49 Povidone Iodine + Ornidazole + Dexpanthenol 50 Salicyclic acid +Aloe vera+ Allantoin +D-Panthenol 51 Silver sulphadiazine +Chlorhexidine Gluconate solution +Allantoin + Aloe vera gel +Vitamin E acetate 52 Sodium salicylate + Zinc gluconate + Pyridoxine HCl 53 Tetracycline + Colistin Sulphate 54 Clomiphene +Ubidecarenone 55 Combikit of Clomiphene Citrate + Estradiol Valerate 56 Flavoxate HCl +Ofloxacin 57 Clomiphene Citrate +N-Acetylcysteine 58 Primerose Oil +Cod liver oil 59 Sildenafil Citrate +Papaverine +L-Arginine 60 Tranexamic acid +Mefenamic acid + Vitamin K1 61 Divalproex Sodium +Oxcarbazepine 62 Divalproex Sodium + Levetiracitam 63 Ergotamine tartrate +Caffeine + Paracetamol +Prochlorperazine maleate 64 Piracetam + Ginkgo biloba extracts + Vinpocetin 65 Ginkgo biloba + methylcobalamin 66 Ginkgo biloba + methylcobalamin + Alpha lipoic acid +Pyridoxine HCl 67 Ginseng Extract +Dried extract of Ginkgo Biloba 68 Meclizine HCl+ Paracetamol + Caffeine 69 Nicergoline + Vinpocetine 70 Gamma Linolenic Acid + Methylcobalamin 71 Beclomethasone Dipropionate + Neomycin Sulphate + Clotrimazole + Lignocaine HCl 72 Boric acid+ Phenylephrine HCl + Naphazoline Nitrate + Menthol + Camphor 73 Naphazoline HCl + Chlorpheniramine Maleate + Zinc Sulphate + Hydroxy Propyl Methyl Cellulose 74 Chlorpheniramine Maleate + Naphazoline HCl + Zinc Sulphate + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 75 Chlorpheniramine Maleate + Naphazoline HCl + Hydroxy Propyl Methyl Cellulose 76 Chlorpheniramine Maleate + Sodium Chloride + Boric Acid + Tetrahydrozoline HCl 77 Chlorpheniramine Maleate + Phenylephrine HCl + Antipyrine 78 Ketorolac Tromethamine + Chlorpheniramine Maleate + Phenylephrine HCl + Hydroxy Propyl Methyl Cellulose 79 Ketorolac Tromethamine + Flurometholone 80 Naphazoline HCl + Zinc Sulphate + Boric Acid + Sodium Chloride+ Chlorpheniramine Maleate 81 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Boric Acid + Borax + Menthol + Camphor 82 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Chlorpheniramine Maleate SN Fixed Dose Combination (FDC) 83 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Menthol + Camphor 84 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 85 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Methylparaben 86 Methenamine + Sodium Benzoate + Benzyl Alcohol 87 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 88 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate + Caffeine 89 Propoxyphene + Chlorpheniramine Maleate 90 Propoxyphene + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 91 Propoxyphene + Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride 92 Sodium Benzoate + Sodium Citrate + Citric Acid 93 Vitamin A Palmitate + Vitamin C + Vitamin E + Vitamin B6 + Vitamin B12 94 Vitamin A Palmitate + Vitamin C + Vitamin E + Niacinamide 95 Vitamin B6 + Vitamin B12 + Vitamin C 96 Vitamin B6 + Vitamin B12 + Niacinamide 97 Vitamin B12 + Vitamin B6 + Vitamin C + Folic Acid 98 Vitamin B12 + Vitamin B6 + Niacinamide + Folic Acid 99 Vitamin C + Vitamin E + Vitamin A + Niacinamide 100 Vitamin D + Calcium + Magnesium 101 Vitamin D + Calcium + Magnesium + Zinc 102 Calcium + Vitamin D + Vitamin K 103 Calcium + Vitamin D + Magnesium + Zinc 104 Calcium + Vitamin D + Vitamin K + Magnesium 105 Calcium + Vitamin D + Vitamin K + Magnesium + Zinc 106 Vitamin E + Vitamin A + Vitamin C + Niacinamide 107 Vitamin E + Vitamin A + Vitamin C + Folic Acid 108 Vitamin E + Vitamin A + Vitamin C + Biotin 109 Vitamin E + Vitamin A + Vitamin C + Vitamin B12 110 Vitamin E + Vitamin C + Folic Acid 111 Vitamin E + Vitamin C + Biotin 112 Vitamin E + Vitamin C + Vitamin B12 113 Vitamin E + Vitamin C + Zinc 114 Calcium + Vitamin D + Omega-3 Fatty Acids 115 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K 116 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Magnesium 117 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Zinc 118 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene 119 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene + Zinc 120 Vitamin C + Vitamin E + Beta-Carotene 121 Vitamin C + Vitamin E + Beta-Carotene + Zinc 122 Vitamin C + Vitamin E + Selenium 123 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids 124 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Magnesium 125 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Zinc 126 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Biotin 127 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 128 Vitamin E + Vitamin A + Vitamin C + Zinc 129 Vitamin E + Vitamin A + Vitamin C + Selenium 130 Vitamin E + Vitamin A + Vitamin C + Biotin 131 Vitamin E + Vitamin A + Vitamin C + Folic Acid + Niacinamide 132 Vitamin E + Vitamin C + Beta-Carotene + Zinc 133 Vitamin C + Vitamin E + Biotin + Folic Acid 134 Vitamin C + Vitamin E + Beta-Carotene + Folic Acid 135 Vitamin C + Vitamin E + Beta-Carotene + Selenium 136 Vitamin E + Vitamin C + Beta-Carotene + Biotin 137 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Biotin 138 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 139 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B12 140 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B6 141 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Folate 142 Calcium + Vitamin D + Magnesium + Vitamin K + Omega-3 Fatty Acids 143 Calcium + Vitamin D + Magnesium + Vitamin K + Biotin 144 Calcium + Vitamin D + Magnesium + Vitamin K + Selenium 145 Calcium + Vitamin D + Magnesium + Vitamin K + Vitamin B12 146 Calcium + Vitamin D + Magnesium + Vitamin K + Folate 147 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B6 148 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B12 149 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Folic Acid 150 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Biotin 151 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Selenium 152 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids 153 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Zinc 154 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Biotin 155 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Selenium 156 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Vitamin B12

上市批准

2024-07-25

·drugs

Hormone-Modulating Therapy May Reduce Dementia Risk in Breast Cancer

THURSDAY, July 25, 2024 -- For women with breast cancer, hormone-modulating therapy (HMT) is associated with reduced risk of Alzheimer disease and related dementias (ADRD), according to a study published online July 16 in JAMA Network Open . Chao Cai, Ph.D., from the University of South Carolina in Columbia, and colleagues examined the association between HMT for breast cancer treatment and the risk of developing ADRD among women aged 65 years or older in a cohort study. Of 18,808 women aged 65 years and older diagnosed with breast cancer between 2007 and 2009, 65.7 and 34.3 percent received and did not receive HMT, respectively, within three years after diagnosis. The researchers found that during an average of 12 years of follow-up, 23.7 and 27.9 percent of HMT users and non-HMT users developed ADRD. Overall, HMT was associated with a reduced relative risk of ADRD (hazard ratio [HR], 0.93). The association varied by race and decreased with age. The greatest reduction in ADRD risk associated with HMT was seen for women aged 65 to 74 years who self-identified as Black (HR, 0.76); among women aged 75 years or older, the association was attenuated (HR, 0.81). The relative risk reduction was lower for women aged 65 to 74 years who self-identified as White (HR, 0.89) and was no longer significant for those aged 75 years or older. No significant association was seen for HMT and ADRD for other races. "Further research is warranted to validate the observed associations in diverse populations and to elucidate the mechanisms underlying our observations," the authors write. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果

100 项与马尿酸乌洛托品相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00855	马尿酸乌洛托品	J01XX05	DB06799

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
泌尿道感染	美国	Esjay Pharma LLC	1976-09-09
感染	美国	Alvogen, Inc.	1967-07-05
下尿路症状	中国	湖南明瑞医药有限责任公司	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03818321 (CTgov)	临床2期	泌尿道感染 \| 盆腔脏器脱垂 \| 尿潴留	185	Methenamine Hippurate 1 g tablet (Methenamine Hippurate With Cranberry)	構壓膚簾夢鬱糧範願顧 = 簾餘醖憲壓簾餘築鹹窪網願蓋鬱鏇齋築憲廠廠 (鏇鑰膚艱鏇鹽簾壓窪鏇, 蓋衊繭鑰選鹽繭獵網製 ~ 窪窪齋衊壓繭網餘簾構) 更多	-	2022-11-14
				Placebo tablet (Placebo With Cranberry)	構壓膚簾夢鬱糧範願顧 = 鹹築範顧積膚範憲蓋窪網願蓋鬱鏇齋築憲廠廠 (鏇鑰膚艱鏇鹽簾壓窪鏇, 觸築餘築衊襯鑰齋鑰網 ~ 廠鹹醖簾襯夢繭選鹹範) 更多
NCT03818321 (Pubmed \| Female Pelvic Med Reconstr Surg)	临床2期	泌尿道感染	185	Methenamine hippurate with cranberry capsules	鹽壓觸築鏇範鹽齋夢製(簾衊襯夢製鑰鏇膚鬱淵) = Overall adherence and level of satisfaction was high 壓糧鏇獵鑰繭構憲艱簾 (鹹積選遞觸壓糧憲膚艱 ) 更多	积极	2022-03-01
				Cranberry with placebo
NCT02358993 (NO-UTI, CTgov)	N/A	导管相关感染 \| 下尿路感染性疾病	201	methenamine hippurate (Methenamine)	鑰鹹製蓋鹹夢積淵壓獵 = 構遞鏇餘製壓窪構廠網膚遞範憲構壓淵鏇鏇製 (構製鏇廠壓淵淵鹹鬱齋, 顧築廠醖鬱願構製繭壓 ~ 選衊構鏇繭製築淵衊獵) 更多	-	2022-02-25
				Ciprofloxacin (Ciprofloxacin)	鑰鹹製蓋鹹夢積淵壓獵 = 餘醖鏇獵繭襯積餘範願膚遞範憲構壓淵鏇鏇製 (構製鏇廠壓淵淵鹹鬱齋, 網築醖願餘鏇餘鬱鹽繭 ~ 觸獵願餘顧淵艱鑰遞蓋) 更多
NCT03077711 (CTgov)	临床4期	泌尿道感染	92	Methenamine hippurate (Patients With Recurrent UTIs Arm 1)	鹹蓋範憲鬱窪鬱淵壓糧(壓夢鏇蓋膚窪願製鏇範) = 衊蓋夢廠選鏇遞醖築夢襯鑰製觸糧選遞範觸鹹 (壓膚範衊夢鬱製鑰醖選, 84.4) 更多	-	2020-01-14
				Trimethoprim (Patients With Recurrent UTIs Arm 2)	鹹蓋範憲鬱窪鬱淵壓糧(壓夢鏇蓋膚窪願製鏇範) = 憲蓋鏇蓋築鬱窪簾餘鬱襯鑰製觸糧選遞範觸鹹 (壓膚範衊夢鬱製鑰醖選, 94) 更多
NCT04077580 (Pubmed \| Cochrane Database Syst Rev)	临床4期	泌尿道感染	2,032	Methenamine hippurate	鹽範鑰選糧糧鑰構襯築(繭願淵鏇壓簾憲壓簾網): RR = 0.56 (95% CI, 0.37 ~ 0.83) 更多	-	2012-10-17
				Methenamine hippurate (Control/No treatment)
NCT04077580 (Pubmed \| J Urol)	临床4期	泌尿道感染	64	Trimethoprim 100 mg	鬱廠網範壓餘襯製願鑰(齋淵繭鹹齋膚製壓壓夢) = 願衊艱餘窪夢襯鹹糧簾夢淵顧膚壓鹹遞築願糧 (範簾遞壓襯襯製蓋壓鹽 )	-	1983-12-01
				Methenamine hippurate 1,000 mg	鬱廠網範壓餘襯製願鑰(齋淵繭鹹齋膚製壓壓夢) = 鑰蓋夢餘製構鏇憲壓繭夢淵顧膚壓鹹遞築願糧 (範簾遞壓襯襯製蓋壓鹽 )